))
Pathways for Treatments in Autism Spectrum Disorder
Archived series ("Inactive feed" status)
When?
This feed was archived on June 24, 2018 15:53 (
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 187804277 series 1553614
Content provided by UC Davis (Audio). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by UC Davis (Audio) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Child psychiatrist Dr. Jeremy Veenstra-VanderWeele explores the two main approaches for developing autism medicines. The first and most common approach is to evaluate a treatment in the total group of people affected by ASD, usually with a small number excluded due to the presence of a known genetic syndrome. The second approach is almost the exact opposite, to study a medication for ASD-related symptoms in a defined genetic syndrome that confers substantial risk of ASD but comprises less than 2% of individuals with ASD. Transformative treatments, though possibly not “cures,” seem most likely to emerge from the second approach, but in a small group of children. In contrast, if the first approach is successful, we can expect a treatment that benefits a larger group of children, but likely benefits them less. Series: "MIND Institute Lecture Series on Neurodevelopmental Disorders" [Health and Medicine] [Professional Medical Education] [Show ID: 29512]
…
continue reading
47 episodes
Share
